Items Tagged ‘General Lung Cancer’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


September 14th, 2016

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug that is planned for use to treat a serious or life-threatening disease […]

View full entry

Tags: advanced, General Lung Cancer, KEYNOTE-024, Lung Cancer, Lung Cancer - Non-Small Cell, Merck, News, nsclc, pembrolizumab, Stages IIIB-IV Lung Cancer - Non-Small Cell


September 13th, 2016

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer

By

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled trial of its kind. As many as 30% of all patients with NSCLC will present with or develop brain metastases. There is currently a routine practice […]

View full entry

Tags: advanced, brain metastases, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, QUARTZ, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, surgery, WBRT


November 16th, 2015

New Lab Test Enables Precision Treatment for Lung Cancer

By

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer is the most common cause of cancer-related deaths in the United States. Opdivo, a PD 1 […]

View full entry

Tags: alk, EGFR, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell, opdivo, PD-L1 levels, xalkori


October 13th, 2015

FDA Approves Keytruda® for Lung Cancer

By

The programmed death (PD-1) inhibitor Keytruda® (pembrolizumab) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the first PD-1 inhibitor and the second immunotherapy available for treatment of this disease. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such […]

View full entry

Tags: General Lung Cancer, KEYNOTE-001 trial, keytruda, Lung Cancer, News, PD-1 inhibitor, PD-L1, pembrolizumab


September 22nd, 2015

Gilotrif Improves Outcomes in Lung Cancer

By

The targeted agent Gilotrif (afatinib) improves outcomes compared to Tarceva (erlotinib) among patients with squamous cell lung cancer. These results were recently published in The Lancet Oncology. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for 75–80% of all lung cancers. Although progress has been made in […]

View full entry

Tags: afatinib, EGFR-positive, General Lung Cancer, gilotrif, Lung Cancer, News, squamous cell lung cancer, targeted agent


August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


February 11th, 2015

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer

By

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported in part by the National Foundation for Cancer Research (NFCR), is a critical milestone on the road to […]

View full entry

Tags: Extensive Lung Cancer - Small Cell, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, lung cancer research, News, Recurrent Lung Cancer - Non-Small Cell, refractory, resistant, Stages IIIB-IV Lung Cancer - Non-Small Cell


February 10th, 2015

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC

By

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However the addition of linifanib did result in greater side effects from treatment. Lung cancer remains the leading cause of cancer-related […]

View full entry

Tags: General Lung Cancer, linifanib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nonsquamous, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


January 21st, 2015

Stereotactic Body Radiation Therapy Improves Survival in Stage IV Non Small Cell Lung Cancer and Represents New Treatment Option

By

The results of a recent clinical trial published in the Journal of Clinical Oncology in patients with stage IV non small cell lung caner (NSCLC) suggest that combining stereotactic body radiation therapy (SBRT) with Tarceva (erlotinib) chemotherapy significantly improve survival. Lung cancer remains the leading cause of cancer death in the United States and abroad, […]

View full entry

Tags: erlotinib, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, radiation, Recurrent Lung Cancer - Non-Small Cell, sbrt, Stages IIIB-IV Lung Cancer - Non-Small Cell, stereotactic body radiation


December 26th, 2013

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis

By

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease is often detected at an advanced, difficult-to-treat stage. Cancer screening involves […]

View full entry

Tags: General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, News, Screening/Prevention Lung Cancer - Non-Small Cell, Screening/Prevention Lung Cancer - Small Cell


August 23rd, 2013

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals

By

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related deaths. This is a grade B draft recommendation. Lung cancer is the leading cause of cancer death among both men and women in […]

View full entry

Tags: General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, News, Screening/Prevention Lung Cancer - Non-Small Cell, Screening/Prevention Lung Cancer - Small Cell